

# EL.EN.

Price (Eu):

# **OUTPERFORM**

47.41

Target Price (Eu): 55.00

1Q16 Results

SECTOR: Industrials

Renato Gargiulo +39-02-77115.318 e-mail: renato.gargiulo@intermonte.it


# Strong Top Line Growth, Record Margins

- Sales growth stronger than expected at 14%, healthy profitability. El.En. reported better than expected 1Q16 revenues of Eu55.2mn (vs. our estimate of Eu51.2mn), up +13.9% YoY, driven by both the medical and industrial segments (+11.6% and +19.4% respectively). Within the medical division, the major growth driver was surgical applications, up +23.6%, but all the key segments performed positively in the quarter (aesthetic +1.2%, physiotherapy +10.6% YoY); industrial sales were boosted by both cutting and marking, up +27.4% and +46.4% YoY respectively. By geographical area, the group posted strong quarterly trends in Italy (+40% YoY) and Rest of the World (+12% YoY, with a rebound in China), while European sales were basically flattish (affected by softer revenues in some countries i.e. Russia and Turkey). The higher sales were associated with a healthy level of profitability, with a 1Q EBITDA margin improvement of around +300bps YoY to 13.9%, while EBIT increased by 51% YoY to Eu6.7mn (vs. our Eu4.8mn forecast), corresponding to a record margin of 12.2% (from 9.2% in 1Q15). Pre-tax profit reached Eu5.8mn (vs. Eu4.7mn expected), after higher than projected net financial items (due to the FOREX effect). The net cash position decreased slightly to Eu27.6mn (from Eu29.8mn at the end of December, in line with
- Positive outlook ahead. 2016 guidance may look conservative. Estimates fine-tuned. Based on current visibility and the improving business environment in several key markets, El.En. reiterated a positive outlook for the remainder of the year. While confirming the recently provided 2016 guidance (pointing to sales growth of around +5% YoY, or Eu229mn, and EBIT in line with 2015, or Eu21.5mn), management seemed more confident about achieving or beating targets, stating that an update will be provided upon the release of 1H results. Following 1Q results, we have slightly raised our sales/EBIT forecasts (by around 1%), now projecting 2016 EBIT of Eu23mn (implying a margin of approx. 9.3% in the remainder of the year vs. 12.2% in 1Q16). At bottom line, this revision is offset by slightly higher net financial items.
- OUTPERFORM reiterated; target price increased to Eu55.0. On the basis of our updated estimates, we set a new target price of Eu55.0 (from Eu53.0). In our view the group should benefit from an increasingly favourable economic environment (with a strong rebound expected in Italy and China), and further potential upside related to a successful penetration of the MonaLisa Touch product in the US market (and its effective introduction into new international areas). Following the disposal of the remaining 4.4% stake in Cynosure for around Eu40mn (on 26th April), the company reached a pro-forma net cash position of around Eu78mn (restated for temporary financial investments), leading in our view to ample room to pursue any potential M&A opportunities or a more generous dividend policy going forwards.

| Key Figures        | 2014A | 2015A | 2016E | 2017E | 2018E |
|--------------------|-------|-------|-------|-------|-------|
| Sales (Eu mn)      | 180   | 218   | 231   | 241   | 252   |
| Ebitda (Eu mn)     | 18    | 26    | 28    | 30    | 32    |
| Net profit (Eu mn) | 17    | 14    | 36    | 16    | 17    |
| EPS - New (Eu)     | 2,290 | 2,979 | 2,777 | 3,278 | 3,473 |
| EPS - Old (Eu)     | 2,290 | 2,979 | 2,888 | 3,251 |       |
| DPS (Eu)           | 1,000 | 1,200 | 1,200 | 1,200 | 1,200 |
| Ratios & Multiples | 2014A | 2015A | 2016E | 2017E | 2018E |
| P/E                | 20,7  | 15,9  | 17,1  | 14,5  | 13,6  |
| Div. Yield         | 2,1%  | 2,5%  | 2,5%  | 2,5%  | 2,5%  |
| EV/Ebitda          | 8,5   | 6,6   | 5,9   | 5,2   | 4,7   |
| ROCE               | 14,2% | 17,0% | 17,3% | 21,1% | 21,6% |
|                    |       |       |       |       |       |

The reproduction of the information, recommendations and research produced by Intermonte SIM contained herein, and of any of its parts, is strictly prohibited. None of the contents of this document may be shared with third parties without Company authorization

### EL.EN. - 12m Performance



| RATING: Unchanged       |          |       |
|-------------------------|----------|-------|
| TARGET PRICE (Eu): from | 53.00 to | 55.00 |
| Change in EPS est:      | 2016E    | 2017E |
|                         | -3.8%    | 0.8%  |

| OI O OIL DI LII L |        |
|-------------------|--------|
| Reuters code:     | ELEN.M |
| Bloomberg code:   | ELN IN |
|                   |        |

| Performance    | 1m    | 3m    | 12m     |
|----------------|-------|-------|---------|
| Absolute       | 20,0% | 21,6% | 25,5%   |
| Relative       | 22,3% | 18,1% | 45,2%   |
| 12 months H/L: |       | 47.4  | 1/33.50 |

## SHAREHOLDER DATA No. of Ord. shares (mn):

STOCK DATA

5 Total No. of shares (mn): Mkt Cap Ord (Eu mn): 229 Total Mkt Cap (Eu mn): 229 Mkt Float - ord (Eu mn): 102 Mkt Float (in %): 44.7% Main shareholder: Cangioli Andrea 15.2%

#### **BALANCE SHEET DATA** 2016 Book value (Eu mn): 178 BVPS (Eu): 36.86 1,3 Net Financial Position (Eu mn): 73 Enterprise value (Eu mn): 164

Please see important disclaimer on the last page of this report



| EN KEY FIGURES          |  | 2014A      | 2015A         | 2016E      | 2017E      | 2018      |
|-------------------------|--|------------|---------------|------------|------------|-----------|
|                         | Fiscal year end  | 31/12/2014 | 31/12/2015    | 31/12/2016 | 31/12/2017 | 31/12/201 |
| PROFIT & LOSS (Eu mn)   | Sales  | 180        | 218           | 231        | 241        | 25        |
|                         | EBITDA   | 18         | 26            | 28         | 30         | 3         |
|                         | EBIT   | 15         | 21            | 23         | 25         | 2         |
|                         | Financial income (charges)                                     | 5          | 1             | (1)        | 1          |           |
|                         | Associates & Others  | 4<br>24    | 0<br>23       | 0<br>23    | 0<br>26    | 2         |
|                         | Pre-tax profit (Loss) Taxes                                    | (6)        |               | (8)        | (8)        | (1        |
|                         | Taxes Tax rate (%)   | -26,3%     | (7)<br>-30,6% | -33,5%     | -30,9%     | -30,9     |
|                         | Minorities & discontinue activities                            | (1)        | (2)           | 21         | (2)        | 30,7      |
|                         | Net profit   | 17         | 14            | 36         | 16         |           |
|                         | Total extraordinary items                                      |            |               |            |            |           |
|                         | Ebitda excl. extraordinary items                               | 18         | 26            | 28         | 30         | ,         |
|                         | Ebit excl. extraordinary items                                 | 14         | 21            | 23         | 25         | :         |
|                         | Net profit restated  | 11         | 14            | 13         | 16         |           |
| PER SHARE DATA (Eu)     | Total shares out (mn) - average fd                             | 5          | 5             | 5          | 5          |           |
| . 2.1. 0.1.1 27 (24)    | EPS stated fd  | 3,424      | 2,979         | 7,441      | 3,278      | 3,4       |
|                         | EPS restated fd  | 2,290      | 2,979         | 2,777      | 3,278      | 3,4       |
|                         | BVPS fd  | 29,632     | 35,287        | 36,865     | 38,942     | 41,2      |
|                         | Dividend per share (ord)                                       | 1,000      | 1,200         | 1,200      | 1,200      | 1,2       |
|                         | Dividend per share (sav)                                       |            |               |            |            |           |
|                         | Dividend pay out ratio (%)                                     | 29,2%      | 40,3%         | 16,1%      | 36,6%      | 34,5      |
| CASH FLOW (Eu mn)       | Gross cash flow  | 21         | 20            | 20         | 22         | :         |
|                         | Change in NWC  | (1)        | (11)          | (4)        | (2)        | (         |
|                         | Capital expenditure  | (11)       | (8)           | (7)        | (7)        | (         |
|                         | Other cash items   | 0          | 0             | 0          | 0          |           |
|                         | Free cash flow (FCF)   | 9          | 2             | 9          | 14         |           |
|                         | Acquisitions, divestments & others                             | 19         | (14)          | 40         | 0          |           |
|                         | Dividend   | (3)        | (5)           | (6)        | (6)        | (         |
|                         | Equity financing/Buy-back                                      |            | 0             |            |            |           |
|                         | Change in Net Financial Position                               | 25         | (17)          | 43         | 8          |           |
| BALANCE SHEET (Eu mn)   | Total fixed assets   | 56         | 81            | 83         | 85         |           |
|                         | Net working capital  | 50         | 60<br>9       | 64         | 66         | (2)       |
|                         | Long term liabilities  | (2)        |               | (31)       | (31)       | (3        |
|                         | Net capital employed   | 103<br>47  | 150<br>30     | 116<br>73  | 120<br>80  | 1.        |
|                         | Net financial position Group equity                            | 151        | 180           | 189        | 201        | 2         |
|                         | Minorities   | 8          | 9             | 11         | 13         | ۷ .       |
|                         | Net equity   | 143        | 170           | 178        | 188        | 19        |
| 175000105 1/41115 /5    |  | 229        | 229           | 229        | 229        |           |
| NTERPRISE VALUE (Eu mn) | Average mkt cap - current Adjustments (associate & minorities) | 229        | 229           | (8)        | (8)        |           |
|                         | Net financial position   | 47         | 30            | 73         | 80         | (         |
|                         | Enterprise value   | 153        | 170           | 164        | 156        | 1.        |
| DATIOC(%)               | EBITDA margin*   | 10,0%      | 11,8%         | 12,0%      | 12,3%      | 12,5      |
| RATIOS(%)               | EBIT margin*   | 7,7%       | 9,9%          | 10,0%      | 10,4%      | 10,5      |
|                         | Gearing - Debt/equity  | -31,3%     | -16,6%        | -38,5%     | -40,1%     | -41,7     |
|                         | Interest cover on EBIT   | nm         | nm            | 46,0       | nm         | n         |
|                         | Debt/Ebitda  | nm         | nm            | nm         | nm         | n         |
|                         | ROCE*  | 14,2%      | 17,0%         | 17,3%      | 21,1%      | 21,6      |
|                         | ROE*   | 12,2%      | 9,2%          | 20,6%      | 8,6%       | 8,7       |
|                         | EV/CE  | 1,4        | 1,3           | 1,2        | 1,3        | 1         |
|                         | EV/Sales   | 0,9        | 0,8           | 0,7        | 0,6        | C         |
|                         | EV/Ebit  | 11,1       | 7,9           | 7,1        | 6,2        | 5         |
|                         | Free Cash Flow Yield   | 4,5%       | 0,8%          | 3,7%       | 5,8%       | 6,1       |
| GROWTH RATES (%)        | Sales  | 14,4%      | 20,9%         | 6,0%       | 4,5%       | 4,5       |
| GROWIN RAIES (%)        | EBITDA*  | 30,7%      | 42,9%         | 7,6%       | 7,8%       | 6,1       |
|                         | EBIT*  | 44,0%      | 55,8%         | 7,0%       | 8,4%       | 6,1       |
|                         | Net profit   | 171,7%     | -13,0%        | 149,8%     | -55,9%     | 6,0       |
|                         | EPS restated   | 81,7%      | 30,1%         | -6,8%      | 18,0%      | 6,0       |

<sup>\*</sup> Excluding extraordinary items

Source: Intermonte SIM estimates

## Results

El.En. Results

| _                | (€ mn)           | 1Q15A  | 1Q16A | 1Q16E  | ΑνΕ    |
|------------------|------------------|--------|-------|--------|--------|
| Sales            |                  | 48,5   | 55,2  | 51,2   | 7,9%   |
|                  | YoY growth %     | 29,1%  | 13,9% | 5,5%   |        |
| EBITDA           |                  | 5,3    | 7,7   | 5,8    | 32,2%  |
| LUITUA           | Ebitda margin %  | 10,9%  | 13,9% | 11,3%  | 02,270 |
|                  | YoY growth %     | 53,8%  | 44,7% | 9,4%   |        |
| Total D&A        |                  | (0,8)  | (0,9) | (1,1)  |        |
| EBIT Adjusted    |                  | 4,5    | 6,7   | 4,8    | 41,5%  |
| -                | Ebit margin %    | 9,2%   | 12,2% | 9,3%   |        |
| EBIT             |                  | 4,5    | 6,7   | 4,8    | 41,5%  |
|                  | Ebit margin %    | 9,2%   | 12,2% | 9,3%   |        |
|                  | YoY growth %     |        | 50,8% | 6,6%   |        |
| Net financials & | & Participations | 1,8    | (0,9) | (0,1)  |        |
| Pretax Profit Ac | ljusted          | 6,3    | 5,8   | 4,7    | 24,4%  |
| Pretax Profit    | •                | 6,3    | 5,8   | 4,7    | 24,4%  |
|                  | Pretax margin %  | 13,0%  | 10,5% | 9,1%   |        |
|                  | YoY growth %     | -20,7% | -7,8% | -25,9% |        |
|                  |                  |        |       |        |        |

Source: Company data and Intermonte Sim

## **Estimates**

El.En. Change in estimates

| (€ mn)             |            | 2015A | 2016E | 2017E |
|--------------------|------------|-------|-------|-------|
|                    |            |       |       |       |
| Sales new          |            | 217,7 | 230,8 | 241,1 |
| Sales old          |            |       | 228,9 | 239,1 |
|                    | % change   |       | 0,8%  | 0,8%  |
| EBITDA new         |            | 25,7  | 27,6  | 29,8  |
| EBITDA old         |            |       | 27,4  | 29,5  |
|                    | % change   |       | 0,7%  | 0,7%  |
| Adjusted EBIT new  |            | 21,5  | 23,0  | 25,0  |
| Adjusted EBIT old  |            |       | 22,8  | 24,7  |
|                    | % change   |       | 0,9%  | 0,9%  |
| Pretax Profit new  |            | 23,1  | 22,5  | 25,6  |
| Pretax Profit old  |            |       | 23,3  | 25,3  |
|                    | % change   |       | -3,4% | 0,8%  |
| Adjusted Group Net | profit new | 14,4  | 13,4  | 15,8  |
| Adjusted Group Net | Profit old |       | 13,9  | 15,7  |
| ·                  | % change   |       | -3,8% | 0,8%  |

Source: Company data and Intermonte Sim estimates





| EI | l.En. | Income | sta | tement | t est | imat | es |
|----|-------|--------|-----|--------|-------|------|----|
|----|-------|--------|-----|--------|-------|------|----|

| (€ mn)                              | 2012A  | 2013A  | 2014A  | 2015A  | 2016E  | 2017E  | CAGR15-17E |
|-------------------------------------|--------|--------|--------|--------|--------|--------|------------|
| Sales                               | 151,2  | 157,4  | 180,0  | 217,7  | 230,8  | 241,1  | 5,2%       |
| YoY growth %                        | 10,1%  | 4,1%   | 14,4%  | 20,9%  | 6,0%   | 4,5%   |            |
| EBITDA                              | 12,5   | 13,7   | 18,0   | 25,7   | 27,6   | 29,8   | 7,7%       |
| Ebitda margin %                     | 8,3%   | 8,7%   | 10,0%  | 11,8%  | 12,0%  | 12,3%  |            |
| YoY growth %                        | 15,7%  | 9,8%   | 30,7%  | 42,9%  | 7,6%   | 7,8%   |            |
| Total D&A                           | (5,0)  | (4,2)  | (2,7)  | (4,2)  | (4,6)  | (4,8)  |            |
| of which non-recurrent              |        |        | 1,5    |        |        |        |            |
| EBIT Reported                       | 7,5    | 9,6    | 15,3   | 21,5   | 23,0   | 25,0   |            |
| Ebit margin %                       | 4,9%   | 6,1%   | 8,5%   | 9,9%   | 10,0%  | 10,4%  |            |
| EBIT Adjusted                       | 7,5    | 9,6    | 13,8   | 21,5   | 23,0   | 25,0   | 7,7%       |
| Ebit margin %                       | 4,9%   | 6,1%   | 7,7%   | 9,9%   | 10,0%  | 10,4%  |            |
| YoY growth %                        | 46,7%  | 28,2%  | 44,0%  | 55,8%  | 7,0%   | 8,4%   |            |
| Net financial charges               | (1,4)  | (1,7)  | 4,6    | 1,6    | (0,5)  | 0,6    |            |
| Other income                        |        | 2,8    | 4,5    |        |        |        |            |
| of which non-recurrent              |        | 2,5    | 4,5    |        |        |        |            |
| Pretax Profit                       | 6,1    | 10,7   | 24,4   | 23,1   | 22,5   | 25,6   | 5,1%       |
| Taxes                               | (3,0)  | (4,3)  | (6,4)  | (7,1)  | (7,5)  | (7,9)  |            |
| tax rate                            | -48,5% | -40,0% | -26,3% | -30,6% | -33,5% | -30,9% |            |
| Income from continued op.           | 3,1    | 6,4    |        |        |        |        |            |
| Income from discontinued op.        | 26,7   | 0,0    |        |        | -      |        |            |
| Net Profit before minority interest | 29,8   | 6,4    | 18,0   | 16,0   | 15,0   | 17,7   | 4,9%       |
| Minority interest from continued or | (1,0)  | (0,3)  | (1,5)  | (1,7)  | (1,6)  | (1,9)  |            |
| Minority interest from discontinued | (5,6)  | 0,0    | 0,0    | 0,0    | 23     | 0,0    |            |
| Reported Group Net Profit           | 23,2   | 6,1    | 16,5   | 14,4   | 35,9   | 15,8   |            |
|                                     | n.m.   | -73,8% | 171,7% | -13,0% | 149,8% | -55,9% |            |
| Adjusted Group Net Profit*          | 2,1    | 3,6    | 11,1   | 14,4   | 13,4   | 15,8   | 4,9%       |
| Net margin %                        | 1,4%   | 2,3%   | 6,1%   | 6,6%   | 5,8%   | 6,6%   |            |
| YoY growth %                        | n.m.   | 68,1%  | 208,7% | 30,1%  | -6,8%  | 18,0%  |            |
|                                     |        |        |        |        |        |        |            |

Source: Company data and Intermonte SIM estimates

EL.EN. Peer Group - Absolute Performances

| Stock            | Price    | Ссу | Mkt cap | 1M     | 3M    | 6M     | YTD    | 1Y     | 2Y     |
|------------------|----------|-----|---------|--------|-------|--------|--------|--------|--------|
| EL.EN.           | 47,41    | EUR | 229     | 20,0%  | 21,6% | 8,0%   | 17,9%  | 25,5%  | 102,0% |
| AMADA CO.        |          | JPY | 421.061 | 5,2%   | 9,1%  | 2,8%   | 1,4%   | -7,0%  | 22,5%  |
| COHERENT INC.    |          | USD | 2.043   | -12,2% | 4,4%  | 33,0%  | 29,2%  | 34,4%  | 46,0%  |
| CYMER            |          | USD |         |        |       |        |        |        |        |
| FIDIA            | 6,29     | EUR | 32      | 0,4%   | -0,1% | -8,8%  | -1,4%  | -22,1% | 112,5% |
| GSI GROUP        |          | USD | 514     | 2,5%   | 18,5% | 9,0%   | 9,4%   | 1,2%   | 23,0%  |
| PRIMA INDUSTRIE  | 11,41    | EUR | 120     | -0,1%  | 7,1%  | -17,9% | -23,0% | -33,4% | -12,2% |
| ROFIN-SINAR TECH |          | USD | 890     | -1,9%  | 51,2% | 11,9%  | 17,4%  | 8,9%   | 38,1%  |
| Mean performance |          |     |         | 2,0%   | 16,0% | 5,4%   | 7,3%   | 1,1%   | 47,4%  |
| Italy FTSE Mib   | 17.498,8 | EUR | 246.539 | -4,2%  | 0,7%  | -21,6% | -18,3% | -25,5% | -15,3% |

Source: FactSet

EL.EN. Peer Group - Multiple Comparison

| Stock            | Price   | Cov    | Ccy Mkt cap | EV/Sales | EV/Sales | EV/Ebitda | EV/Ebitda | EV/Ebit | EV/Ebit | P/E  | P/E  | Div Yield | Div Yield |
|------------------|---------|--------|-------------|----------|----------|-----------|-----------|---------|---------|------|------|-----------|-----------|
| SIOCK            | Price   | CCy IV |             | 2016     | 2017     | 2016      | 2017      | 2016    | 2017    | 2016 | 2017 | 2016      | 2017      |
| EL.EN.           | 47,41   | EUR    | 229         | 0,7      | 0,6      | 5,9       | 5,2       | 7,1     | 6,2     | 17,1 | 14,5 | 2,5%      | 2,5%      |
| AMADA CO.        | 1180,00 | JPY    | 421.061     | 1,2      | 1,2      | 8,1       | 7,9       | 9,9     | 9,7     | 16,7 | 16,7 | 3,0%      | 3,0%      |
| COHERENT INC.    | 84,11   | USD    | 2.043       | 2,1      | 2,1      | 11,2      | 9,7       | 14,6    | 12,5    | 21,6 | 18,5 |           |           |
| CYMER            |         | USD    |             |          |          |           |           |         |         |      |      |           |           |
| FIDIA            | 6,29    | EUR    | 32          | 0,5      | 0,4      | 4,7       | 4,0       | 5,8     | 4,9     | 10,0 | 9,0  | 6,4%      | 6,4%      |
| GSI GROUP        | 14,90   | USD    | 514         |          |          |           |           |         |         | 14,9 | 13,3 |           |           |
| PRIMA INDUSTRIE  | 11,41   | EUR    | 120         | 0,6      | 0,5      | 6,0       | 4,6       | 9,8     | 6,8     | 11,9 | 7,7  | 2,2%      | 3,0%      |
| ROFIN-SINAR TECH | 31,45   | USD    | 890         | 1,4      | 1,5      | 9,8       | 11,3      | 12,9    | 14,6    | 21,5 | 25,1 | 0,0%      | 0,0%      |
| Median           |         |        |             | 1,2      | 1,2      | 8,1       | 7,9       | 9,9     | 9,7     | 15,8 | 15,0 | 2,6%      | 3,0%      |

Source: Intermonte SIM estimates for covered companies, FactSet consensus estimates for peer group

## El.En. Peer Group - Absolute Performances

| Stock                   | Price | Ссу  | Mkt cap | 1M     | 3M    | 6M     | YTD    | 1Y     | 2Y     |
|-------------------------|-------|------|---------|--------|-------|--------|--------|--------|--------|
| Cynosure                | 46,4  | USD  | 1.056,8 | 3,1%   | 23,2% | 20,3%  | -0,2%  | 31,8%  | 161,4% |
| El.En                   | 47,4  | Euro | 228,7   | 20,0%  | 21,6% | 8,0%   | 17,9%  | 25,5%  | 102,0% |
| Syneron Medical Ltd     | 6,1   | USD  | 211,3   | -4,4%  | -3,1% | -10,6% | -14,2% | -40,8% | -21,1% |
| Cutera, Inc.            | 8,8   | USD  | 115,6   | -16,5% | -9,4% | -28,4% | -24,9% | -29,0% | 23,4%  |
| BIOLASE, Inc.           | 1,1   | USD  | 63,7    | -9,8%  | 45,0% | 20,9%  | 41,3%  | -39,8% | -20,3% |
| ZELTIQ Aesthetics, Inc. | 21,0  | USD  | 828,0   | -20,3% | 13,5% | -30,0% | -20,1% | -17,0% | 82,1%  |
| Medical avg             |       |      |         | -12,7% | 11,5% | -12,0% | -4,5%  | -31,7% | 16,0%  |
|                         |       |      |         |        |       |        |        |        |        |
| Italy FTSE Mib          |       |      |         | -2,6%  | 3,5%  | -16,9% | -15,3% | -19,5% | -13,1% |

Source: Factset

## El.En. Peer Group - Multiple Comparison

| Stock                   | Price | Ссу        | Mkt cap | EV/Sales<br>2016 | EV/Sales<br>2017 | P/E 2016 | P/E 2017 | EV/EBITDA<br>2016 | EV/EBITDA<br>2017 |
|-------------------------|-------|------------|---------|------------------|------------------|----------|----------|-------------------|-------------------|
| El.En                   | 47,4  | EUR - Euro | 228,7   | 0,7              | 0,6              | 17,1     | 14,5     | 5,9               | 5,2               |
| Syneron Medical Ltd     | 6,1   | USD        | 211,3   | 0,5              | 0,5              | 25,1     | 13,9     |                   |                   |
| Cynosure                | 46,4  | USD        | 1.056,8 | 2,3              | 2,1              | 36,2     | 24,6     | 15,8              | 11,9              |
| Cutera, Inc.            | 8,8   | USD        | 115,6   | 0,8              | 0,7              | 18,6     | 12,7     | 20,1              | 12,7              |
| BIOLASE, Inc.           | 1,1   | USD        | 63,7    | 1,3              | 1,2              |          |          |                   |                   |
| ZELTIQ Aesthetics, Inc. | 21,0  | USD        | 828,0   | 2,8              | 2,4              |          | 51,6     | 33,9              | 16,3              |
| Medical avg             |       |            |         | 1,3              | 1,2              | 25,1     | 19,2     | 20,1              | 12,7              |

Source: Factset consensus estimates for peer group, Intermonte estimates for El.En





### DISCLAIMER (for more details go to http://intermonte.it/ disclosures.asp)

#### IMPORTANT DISCLOSURES

MPORTANT DISCLOSURES
The reproduction of the information, recommendations and research produced by Intermonte SIM contained herein and of any its parts is strictly prohibited. None of the contents of this document may be shared with third parties without authorisation from Intermonte.

This report is directed exclusively at market professional and other institutional investors (institutions) and is not for distribution to person other than "Institution" ("Non-Institution"), who should not rely on this material. Moreover, any investment or service to which this report may relate will not be made available to Non-Institution.

The information and data in this report have been obtained from sources which we believe to be reliable, although the accuracy of these cannot be guaranteed by the Intermonte. In the event that there be any doubt as to their reliability, this will be clearly indicated. The main purpose of the report is to offer up-to-date and accurate information in accordance with regulations in force covering "recommendations" and is not intended nor should it be construed as a solicitation to buy or sell securities.

This disclaimer is constantly updated on Intermontes's website www.intermonte.it under DISCLOSURES. Valuations and recommendations can be found in the text of the most recent research and/or reports on the companies in question.

### ANALYST CERTIFICATION

ANALYSI CERTIFICATION
For each company mentioned in this report the respective research analyst hereby certifies that all of the views expressed in this research report accurately reflect the analyst's personal views about any or all of the subject issuer (s) or securifies. The analyst (s) also certify that no part of their compensation was, is or will be directly or indirectly related to the specific recommendation or view in this report.

The analyst (s) responsible for preparing this research report receive(s) compensation that is based upon various factors, including intermonte's total profits, a portion of which is generated by Intermonte's corporate finance activities, although this is minimal in comparison to that generated by brokerage activities.

Intermonte's internal procedures and codes of conduct are aimed to ensure the impartiality of its financial analysts. The exchange of information between the Corporate Finance sector and the Research Department is prohibited, as is the exchange of information between the latter and the proprietary equity desk in order to prevent conflicts of interest when recommendations are made.

CUIDE TO FUNDAMENTAL RESEARCH
Reports on all companies listed on the S&PMIB40 Index, most of those on the MIDEX Index and the main small caps (regular coverage) are published at least once per quarter to comment on results and important newsflow.

A draft copy of each report may be sent to the subject company for its information (without target price and/or recommendations), but unless expressly stated in the text of the report, no changes are made before it is published.

Explanation of our ratings system:

BUY stock expected to outperform the market by over 25% over a 12 month period:

OUTPERFORM: stock expected to outperform the market by between 10% and 25% over a 12 month period:

NEURAL: stock performance expected at between +10% and -10% compared to the market over a 12 month period:

SELL: stock expected to underperform the market by between -10% and -25% over a 12 month period.

The stock price indicated is the reference price on the day prior to the publication of the report.

## CURRENT INVESTMENT RESEARCH RATING DISTRIBUTIONS

Intermonte SIM is authorised by CONSOB to provide investment services and is listed at n° 246 in the register of brokerage firms. As at 31 March 2016 Intermonte's Research Department covered 149 companies.

Intermonte's distribution of stock ratings is as follows: OUTPERFORM: 42.95% NEUTRAL: 31.11% UNDERPERFORM: 0.0%

SELL: 0.0%

The distribution of stock ratings for companies which have received corporate finance services from Intermonte in the last 12 months (45 in total) is as follows

BUY: 22.22% OUTPERFORM: 46.67% NEUTRAL: 18.42% UNDERPERFORM: 0.00% SELL: 0.00%

## CONFLICT OF INTEREST

In order to disclose its possible conflicts of interest Intermonte SIM states that:

- o within the last year, Intermonte SIM managed or co-managed/is managing or is co-managing (see companies indicated in bold type) an Institutional Offering and/or managed or co-managing or is co-managing (see companies in indicated in bold type) an Institutional Offering and/or managed or co-managing or is co-managin
- Intermonte SIM is Specialist and/or Corporate Broker and/or Sponsor and/or Broker in charge of the share buy back activity of the following Companies: Aedes, Aeroporto di Bologna, Ascopiave, B&C Speakers, Banca Ifis, Banca Sistema, Banzai, Be, Bolzoni, BOMI, Carraro, Cattolica Assicurazioni, Cementir, Credito Valtellinese, Datalogic, DeA capital, DigiTouch, DigiTal bros, El.En, Emak, ERG, Ferrovie Nord Milano, Fintel Energia Group, Gefran, Greentlaly1, GO Internet, IGD, II Sole 24 Ore, IWB, Kinexia, Lucisano Media Group, LU VE, Mondo TV, OF Alpha Immobiliare, Co of Beta Immobiliare, Recordati, Reno de Medici, Repty, Retelit, Saes Getters, Servizi Italia, Sesa, SITI B&T Group S.p.A., Snai, Tamburi Investment Partners, Tesmec, TBS Group, Tecnoinvestimenti, Ternienergia, TXT e-solutions, Vittoria Assicurazioni.
- Intermonte SIM acted as Global Coordinator in the Greentlaly1 IPO on the AIM Italia market and will receive a success fee if a business combination is approved by the shareholders. Intermonte SIM SpA and its subsidiaries do not hold a stake equal to or over 1% of common equity securities and/or warrants of any of the aforementioned subject companies, with the exception of: Greentlaly1.
- Intermonte SIM SpA has provided in the last 12 months / provides / may provide investment banking services to the following companies: Aedes, Conafi, Bolzoni, CNRC/Marco Polo Industrial Holding (on Pirelli shares), Hitachi (on Ansaldo STS shares), Kinexia, Prelios, RCS, Seat Pagine Gialle, IPO Challenger/IWB. Intermonte SIM SpA may provide investment banking services to RCS MediaGroup, also in connection with the share exchange offer promoted by Cairo Communication

| Stock NAME           | EL.EN.     |                       |            |  |
|----------------------|------------|-----------------------|------------|--|
| Current Recomm:      | OUTPERFORM | Previous Recomm:      | OUTPERFORM |  |
| Current Target (Eu): | 55.00      | Previous Target (Eu): | 53.00      |  |
| Current Price (Eu):  | 47.41      | Previous Price (Eu):  | 40.60      |  |
| Date of report:      | 18/05/2016 | Date of last report:  | 16/03/2016 |  |

e Copyright 2010 by Intermonte SIM - All rights reserved
It is a violation of national and international copyright laws to reproduce all or part of this publication by email, xerography, facsimile or any other means. The Copyright laws impose heavy liability for such infringement. The Reports of Intermonte SIM are provided to its clients only. If you are not a client of Intermonte SIM and receive emailed, faxed or copied versions of the reports from a source other than Intermonte SIM you are violating the Copyright Laws. This document is not for attribution in any publication, and you should not disseminate, distribute or copy this e-mail without the explicit written consent of Intermonte SIM.

INTERMONIE will take legal action against anybody transmitting/publishing its Research products without its express authorization.

INTERMONIE Sim strongly believes its research product on Italian equities is a value added product and deserves to be adequately paid.

Intermonte Sim sales representatives can be contacted to discuss terms and conditions to be supplied the INTERMONIE research product.

INTERMONTE SIM is MIFID compliant - for our Best Execution Policy please check our Website www.intermonte.it/mifid Further information is available